Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
BMC Cancer
Published in: BMC Cancer 1/2024

Open Access 01-12-2024 | Ovarian Cancer | Research

ST14 interacts with TMEFF1 and is a predictor of poor prognosis in ovarian cancer

Authors: Xin Nie, Lingling Gao, Mingjun Zheng, Shuang Wang, Caixia Wang, Xiao Li, Ouxuan Liu, Rui Gou, Juanjuan Liu, Bei Lin

Published in: BMC Cancer | Issue 1/2024

Login to get access

Abstract

TMEFF1 is a new protein involved in the physiological functions of the central nervous system, and we previously reported TMEFF1 can promote ovarian cancer. ST14 was determined to be involved in the processes of epidermal differentiation, epithelial cell integrity, and vascular endothelial cell migration, etc. The relationship between ST14 and TMEFF1 in the ovary remains unknown. In this study, we detected the expression of ST14 and TMEFF1 in 130 different ovarian cancer tissues through immunohistochemistry. We determined ST14 and TMEFF1 were highly expressed in ovarian cancer, indicating a higher degree of tumor malignancy and a worse prognosis. Tissues significantly expressing ST14 also highly expressed TMEFF1, and the expression of the two proteins was positively correlated. Consistently, immunofluorescence double staining demonstrated the co-localization of ST14 and TMEFF1 in the same region, and immunoprecipitation confirmed the interaction between ST14 and TMEFF1. TMEFF1 expression was also reduced after knocking down ST14 through Western blot. MTT, wound healing and Transwell assays results determined that knockdown of ST14 inhibited proliferation, migration and invasion of ovarian cancer cells in vitro, but the inhibitory effect was restored after adding TMEFF1 exogenous protein. Gene Ontology and Kyoto Encyclopedia of Genes and Genomes pathways analysis showed that ST14 and its related genes were enriched in the processes of epithelial formation, intercellular adhesion, protein localization, and mitosis regulation. We also clarified the kinase, microRNA, and transcription factor target networks and the impact of genetic mutations on prognosis. Overall, high expression of ST14 and TMEFF1 in ovarian cancer predicts higher tumor malignancy and a worse prognosis. ST14 and TMEFF1 co-localize and interact with each other in ovarian cancer. ST14 can regulate TMEFF1 expression to promote proliferation, migration and invasion of ovarian cancer cells. We speculate that the relationship between ST14 and TMEFF1 in ovarian cancer could become a potential target for anti-cancer therapy.
Appendix
Available only for authorised users
Literature
1.
Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2022. Cancer J Clin. 2022;72(1):7–33.CrossRef
2.
Dalmartello M, La Vecchia C, Bertuccio P, Boffetta P, Levi F, Negri E, Malvezzi M. European cancer mortality predictions for the year 2022 with focus on ovarian cancer. Annals Oncology: Official J Eur Soc Med Oncol. 2022;33(3):330–9.CrossRef
3.
Eib DW, Martens GJ. A novel transmembrane protein with epidermal growth factor and follistatin domains expressed in the hypothalamo-hypophysial axis of Xenopus laevis. J Neurochem. 1996;67(3):1047–55.PubMedCrossRef
4.
Eib DW, Holling TM, Zwijsen A, Dewulf N, de Groot E, van den Eijnden-van Raaij AJ, Huylebroeck D, Martens GJ. Expression of the follistatin/EGF-containing transmembrane protein M7365 (tomoregulin-1) during mouse development. Mech Dev. 2000;97(1–2):167–71.PubMedCrossRef
5.
Chang C, Eggen BJ, Weinstein DC, Brivanlou AH. Regulation of nodal and BMP signaling by tomoregulin-1 (X7365) through novel mechanisms. Dev Biol. 2003;255(1):1–11.PubMedCrossRef
6.
Gery S, Yin D, Xie D, Black KL, Koeffler HP. TMEFF1 and brain tumors. Oncogene. 2003;22(18):2723–7.PubMedCrossRef
7.
Noelker C, Schwake M, Balzer-Geldsetzer M, Bacher M, Popp J, Schlegel J, Eggert K, Oertel WH, Klockgether T, Dodel RC. Differentially expressed gene profile in the 6-hydroxy-dopamine-induced cell culture model of Parkinson’s disease. Neurosci Lett. 2012;507(1):10–5.PubMedCrossRef
8.
Oshimori N, Fuchs E. Paracrine TGF-beta signaling counterbalances BMP-mediated repression in hair follicle stem cell activation. Cell Stem Cell. 2012;10(1):63–75.PubMedPubMedCentralCrossRef
9.
Ge W, Hu H, Ding K, Sun L, Zheng S. Protein interaction analysis of ST14 domains and their point and deletion mutants. J Biol Chem. 2006;281(11):7406–12.PubMedCrossRef
10.
Nie X, Liu C, Guo Q, Zheng MJ, Gao LL, Li X, Liu DW, Zhu LC, Liu JJ, Lin B. TMEFF1 overexpression and its mechanism for tumor promotion in ovarian cancer. Cancer Manage Res. 2019;11:839–55.CrossRef
11.
Damalanka VC, Han Z, Karmakar P, O’Donoghue AJ, La Greca F, Kim T, Pant SM, Helander J, Klefström J, Craik CS, et al. Discovery of Selective Matriptase and Hepsin Serine protease inhibitors: useful chemical tools for Cancer Cell Biology. J Med Chem. 2019;62(2):480–90.PubMedCrossRef
12.
13.
Chen YW, Wang JK, Chou FP, Wu BY, Hsiao HC, Chiu H, Xu Z, Baksh ANH, Shi G, Kaul M, et al. Matriptase regulates proliferation and early, but not terminal, differentiation of human keratinocytes. J Invest Dermatol. 2014;134(2):405–14.PubMedCrossRef
14.
Chen CY, Chen CJ, Lai CH, Wu BY, Lee SP, Johnson MD, Lin CY, Wang JK. Increased matriptase zymogen activation by UV irradiation protects keratinocyte from cell death. J Dermatol Sci. 2016;83(1):34–44.PubMedCrossRef
15.
List K, Kosa P, Szabo R, Bey AL, Wang CB, Molinolo A, Bugge TH. Epithelial integrity is maintained by a matriptase-dependent proteolytic pathway. Am J Pathol. 2009;175(4):1453–63.PubMedPubMedCentralCrossRef
16.
Kim C, Lee HS, Lee D, Lee SD, Cho EG, Yang SJ, Kim SB, Park D, Kim MG. Epithin/PRSS14 proteolytically regulates angiopoietin receptor Tie2 during transendothelial migration. Blood. 2011;117(4):1415–24.PubMedCrossRef
17.
Kim KY, Yoon M, Cho Y, Lee KH, Park S, Lee SR, Choi SY, Lee D, Yang C, Cho EH, et al. Targeting metastatic breast cancer with peptide epitopes derived from autocatalytic loop of Prss14/ST14 membrane serine protease and with monoclonal antibodies. J Experimental Clin cancer Research: CR. 2019;38(1):363.PubMedCentralCrossRef
18.
Zarif JC, Lamb LE, Schulz VV, Nollet EA, Miranti CK. Androgen receptor non-nuclear regulation of prostate cancer cell invasion mediated by Src and matriptase. Oncotarget. 2015;6(9):6862–76.PubMedPubMedCentralCrossRef
19.
Ahmad F, Ahmed I, Nasir A, Umair M, Shahzad S, Muhammad D, Santos-Cortez RLP, Leal SM, Ahmad W. A disease-causing novel missense mutation in the ST14 gene underlies autosomal recessive ichthyosis with hypotrichosis syndrome in a consanguineous family. Eur J Dermatology: EJD. 2018;28(2):209–16.CrossRef
20.
Nie X, Zheng M, Gao L, Hu Y, Zhuang Y, Li X, Zhu L, Liu J, Lin B. Interaction between TMEFF1 and AHNAK proteins in ovarian cancer cells: implications for clinical prognosis. Int Immunopharmacol. 2022;107:108726.PubMedCrossRef
21.
Zhuang H, Tan M, Liu J, Hu Z, Liu D, Gao J, Zhu L, Lin B. Human epididymis protein 4 in association with annexin II promotes invasion and metastasis of ovarian cancer cells. Mol Cancer. 2014;13:243.PubMedPubMedCentralCrossRef
22.
Wang S, Wang C, Hu Y, Li X, Jin S, Liu O, Gou R, Zhuang Y, Guo Q, Nie X, et al. ZNF703 promotes tumor progression in ovarian cancer by interacting with HE4 and epigenetically regulating PEA15. J Experimental Clin cancer Research: CR. 2020;39(1):264.PubMedCentralCrossRef
23.
Xu H, Zhang H, Liu G, Kong L, Zhu X, Tian X, Zhang Z, Zhang R, Wu Z, Tian Y, et al. Coumarin-based fluorescent probes for super-resolution and dynamic Tracking of lipid droplets. Anal Chem. 2019;91(1):977–82.PubMedCrossRef
24.
Zinchuk V, Grossenbacher-Zinchuk O. Recent advances in quantitative colocalization analysis: focus on neuroscience. Prog Histochem Cytochem. 2009;44(3):125–72.PubMedCrossRef
25.
Nie X, Liu D, Zheng M, Li X, Liu O, Guo Q, Zhu L, Lin B. HERPUD1 promotes ovarian cancer cell survival by sustaining autophagy and inhibit apoptosis via PI3K/AKT/mTOR and p38 MAPK signaling pathways. BMC Cancer. 2022;22(1):1338.PubMedPubMedCentralCrossRef
26.
Rhodes DR, Kalyana-Sundaram S, Mahavisno V, Varambally R, Yu J, Briggs BB, Barrette TR, Anstet MJ, Kincead-Beal C, Kulkarni P, et al. Oncomine 3.0: genes, pathways, and networks in a collection of 18,000 cancer gene expression profiles. Neoplasia (New York NY). 2007;9(2):166–80.CrossRef
27.
Rhodes DR, Yu J, Shanker K, Deshpande N, Varambally R, Ghosh D, Barrette T, Pandey A, Chinnaiyan AM. ONCOMINE: a cancer microarray database and integrated data-mining platform. Neoplasia (New York NY). 2004;6(1):1–6.CrossRef
28.
Chandrashekar DS, Bashel B, Balasubramanya SAH, Creighton CJ, Ponce-Rodriguez I, Chakravarthi B, Varambally S. UALCAN: a portal for facilitating Tumor Subgroup Gene expression and survival analyses. Neoplasia (New York NY). 2017;19(8):649–58.CrossRef
29.
Tang Z, Li C, Kang B, Gao G, Li C, Zhang Z. GEPIA: a web server for cancer and normal gene expression profiling and interactive analyses. Nucleic Acids Res. 2017;45(W1):W98–w102.PubMedPubMedCentralCrossRef
30.
Vasaikar SV, Straub P, Wang J, Zhang B. LinkedOmics: analyzing multi-omics data within and across 32 cancer types. Nucleic Acids Res. 2018;46(D1):D956–d963.PubMedCrossRef
31.
Liberzon A, Subramanian A, Pinchback R, Thorvaldsdóttir H, Tamayo P, Mesirov JP. Molecular signatures database (MSigDB) 3.0. Bioinf (Oxford England). 2011;27(12):1739–40.
32.
Kanehisa M, Furumichi M, Sato Y, Ishiguro-Watanabe M, Tanabe M. KEGG: integrating viruses and cellular organisms. Nucleic Acids Res. 2021;49(D1):D545–d551.PubMedCrossRef
33.
Zhou Y, Zhou B, Pache L, Chang M, Khodabakhshi AH, Tanaseichuk O, Benner C, Chanda SK. Metascape provides a biologist-oriented resource for the analysis of systems-level datasets. Nat Commun. 2019;10(1):1523.ADSPubMedPubMedCentralCrossRef
34.
Cerami E, Gao J, Dogrusoz U, Gross BE, Sumer SO, Aksoy BA, Jacobsen A, Byrne CJ, Heuer ML, Larsson E, et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov. 2012;2(5):401–4.PubMedCrossRef
35.
Gao J, Aksoy BA, Dogrusoz U, Dresdner G, Gross B, Sumer SO, Sun Y, Jacobsen A, Sinha R, Larsson E, et al. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci Signal. 2013;6(269):pl1.PubMedPubMedCentralCrossRef
36.
Warde-Farley D, Donaldson SL, Comes O, Zuberi K, Badrawi R, Chao P, Franz M, Grouios C, Kazi F, Lopes CT et al. The GeneMANIA prediction server: biological network integration for gene prioritization and predicting gene function. Nucleic Acids Res 2010, 38(Web Server issue):W214–220.
37.
Szklarczyk D, Gable AL, Lyon D, Junge A, Wyder S, Huerta-Cepas J, Simonovic M, Doncheva NT, Morris JH, Bork P, et al. STRING v11: protein-protein association networks with increased coverage, supporting functional discovery in genome-wide experimental datasets. Nucleic Acids Res. 2019;47(D1):D607–d613.PubMedCrossRef
38.
Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2021. Cancer J Clin. 2021;71(1):7–33.
39.
Shi YE, Torri J, Yieh L, Wellstein A, Lippman ME, Dickson RB. Identification and characterization of a novel matrix-degrading protease from hormone-dependent human breast cancer cells. Cancer Res. 1993;53(6):1409–15.PubMed
40.
Ding KF, Sun LF, Ge WT, Hu HG, Zhang SZ, Zheng S. Effect of SNC19/ST14 gene overexpression on invasion of colorectal cancer cells. World J Gastroenterol. 2005;11(36):5651–4.PubMedPubMedCentralCrossRef
41.
Tsai CH, Teng CH, Tu YT, Cheng TS, Wu SR, Ko CJ, Shyu HY, Lan SW, Huang HP, Tzeng SF, et al. HAI-2 suppresses the invasive growth and metastasis of prostate cancer through regulation of matriptase. Oncogene. 2014;33(38):4643–52.PubMedCrossRef
42.
Kosa P, Szabo R, Molinolo AA, Bugge TH. Suppression of Tumorigenicity-14, encoding matriptase, is a critical suppressor of colitis and colitis-associated colon carcinogenesis. Oncogene. 2012;31(32):3679–95.PubMedCrossRef
43.
Jin JS, Hsieh DS, Loh SH, Chen A, Yao CW, Yen CY. Increasing expression of serine protease matriptase in ovarian tumors: tissue microarray analysis of immunostaining score with clinicopathological parameters. Mod Pathology: Official J United States Can Acad Pathol Inc. 2006;19(3):447–52.CrossRef
44.
Tanimoto H, Shigemasa K, Tian X, Gu L, Beard JB, Sawasaki T, O’Brien TJ. Transmembrane serine protease TADG-15 (ST14/Matriptase/MT-SP1): expression and prognostic value in ovarian cancer. Br J Cancer. 2005;92(2):278–83.PubMedCrossRef
45.
Oberst MD, Johnson MD, Dickson RB, Lin CY, Singh B, Stewart M, Williams A, al-Nafussi A, Smyth JF, Gabra H, et al. Expression of the serine protease matriptase and its inhibitor HAI-1 in epithelial ovarian cancer: correlation with clinical outcome and tumor clinicopathological parameters. Clin cancer Research: Official J Am Association Cancer Res. 2002;8(4):1101–7.
46.
Kauppinen JM, Kosma VM, Soini Y, Sironen R, Nissinen M, Nykopp TK, Kärjä V, Eskelinen M, Kataja V, Mannermaa A. ST14 gene variant and decreased matriptase protein expression predict poor breast cancer survival. Cancer Epidemiol Biomarkers Prevention: Publication Am Association Cancer Res Cosponsored Am Soc Prev Oncol. 2010;19(9):2133–42.CrossRef
47.
Salmaninejad A, Zamani MR, Pourvahedi M, Golchehre Z, Hosseini Bereshneh A, Rezaei N. Cancer/Testis antigens: expression, regulation, Tumor Invasion, and use in immunotherapy of cancers. Immunol Investig. 2016;45(7):619–40.CrossRef
48.
Grizzi F, Mirandola L, Qehajaj D, Cobos E, Figueroa JA, Chiriva-Internati M. Cancer-testis antigens and immunotherapy in the light of cancer complexity. Int Rev Immunol. 2015;34(2):143–53.PubMedCrossRef
49.
Nie X, Gao L, Zheng M, Wang C, Wang S, Li X, Qi Y, Zhu L, Liu J, Lin B. Overexpression of TMEFF1 in Endometrial Carcinoma and the mechanism underlying its Promotion of Malignant Behavior in Cancer cells. J Cancer. 2021;12(19):5772–88.PubMedPubMedCentralCrossRef
50.
Wu SR, Cheng TS, Chen WC, Shyu HY, Ko CJ, Huang HP, Teng CH, Lin CH, Johnson MD, Lin CY, et al. Matriptase is involved in ErbB-2-induced prostate cancer cell invasion. Am J Pathol. 2010;177(6):3145–58.PubMedPubMedCentralCrossRef
51.
Lee HS, Kim C, Kim SB, Kim MG, Park D. Epithin, a target of transforming growth factor-beta signaling, mediates epithelial-mesenchymal transition. Biochem Biophys Res Commun. 2010;395(4):553–9.PubMedCrossRef
52.
53.
Lili LN, Matyunina LV, Walker LD, Wells SL, Benigno BB, McDonald JF. Molecular profiling supports the role of epithelial-to-mesenchymal transition (EMT) in ovarian cancer metastasis. J Ovarian Res. 2013;6(1):49.PubMedPubMedCentralCrossRef
54.
Moreno-Bueno G, Cubillo E, Sarrio D, Peinado H, Rodriguez-Pinilla SM, Villa S, Bolos V, Jorda M, Fabra A, Portillo F, et al. Genetic profiling of epithelial cells expressing E-cadherin repressors reveals a distinct role for snail, slug, and E47 factors in epithelial-mesenchymal transition. Cancer Res. 2006;66(19):9543–56.PubMedCrossRef
55.
Bolos V, Peinado H, Perez-Moreno MA, Fraga MF, Esteller M, Cano A. The transcription factor slug represses E-cadherin expression and induces epithelial to mesenchymal transitions: a comparison with snail and E47 repressors. J Cell Sci. 2003;116(Pt 3):499–511.PubMedCrossRef
56.
Zoratti GL, Tanabe LM, Hyland TE, Duhaime MJ, Colombo É, Leduc R, Marsault E, Johnson MD, Lin CY, Boerner J, et al. Matriptase regulates c-Met mediated proliferation and invasion in inflammatory breast cancer. Oncotarget. 2016;7(36):58162–73.PubMedPubMedCentralCrossRef
57.
Uchida T, Wada K, Akamatsu T, Yonezawa M, Noguchi H, Mizoguchi A, Kasuga M, Sakamoto C. A novel epidermal growth factor-like molecule containing two follistatin modules stimulates tyrosine phosphorylation of erbB-4 in MKN28 gastric cancer cells. Biochem Biophys Res Commun. 1999;266(2):593–602.PubMedCrossRef
58.
Wee P, Wang Z. Epidermal growth factor receptor cell Proliferation Signaling pathways. Cancers 2017, 9(5).
59.
60.
List K, Szabo R, Molinolo A, Sriuranpong V, Redeye V, Murdock T, Burke B, Nielsen BS, Gutkind JS, Bugge TH. Deregulated matriptase causes ras-independent multistage carcinogenesis and promotes ras-mediated malignant transformation. Genes Dev. 2005;19(16):1934–50.PubMedPubMedCentralCrossRef
61.
Arano T, Fujisaki S, Ikemoto MJ. Identification of tomoregulin-1 as a novel addicsin-associated factor. Neurochem Int. 2014;71:22–35.PubMedCrossRef
62.
Harms PW, Chang C. Tomoregulin-1 (TMEFF1) inhibits nodal signaling through direct binding to the nodal coreceptor Cripto. Genes Dev. 2003;17(21):2624–9.PubMedPubMedCentralCrossRef
Metadata
Title
ST14 interacts with TMEFF1 and is a predictor of poor prognosis in ovarian cancer
Authors
Xin Nie
Lingling Gao
Mingjun Zheng
Shuang Wang
Caixia Wang
Xiao Li
Ouxuan Liu
Rui Gou
Juanjuan Liu
Bei Lin
Publication date
01-12-2024
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2024
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/s12885-024-11958-8

Other articles of this Issue 1/2024

BMC Cancer 1/2024 Go to the issue

Study Protocol

Pre-operative vs. post-operative stereotactic radiosurgery for operative metastatic brain tumors: study protocol for a phase III clinical trial

Research

Germline mutations in BRCA1 and BRCA2 among Brazilian women with ovarian cancer treated in the Public Health System

Retraction Note

Retraction Note: Swainsonine represses glioma cell proliferation, migration and invasion by reduction of miR-92a expression

Research

Biplex quantitative PCR to detect transcriptionally active human papillomavirus 16 from patient saliva

Research

Tenascin C as a novel zinc finger protein 750 target regulating the immunogenicity via DNA damage in lung squamous cell carcinoma

Research

The depth of perineural invasion is an independent prognostic factor for stage II colorectal cancer
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits